1
|
Dai B, Su Q, Liu X, Mi X, Dou L, Zhou D, Su Y, Shen T, Zhang Y, Xu W, Tan X, Wang D. 2, 2-dimethylthiazolidine hydrochloride protects against experimental contrast-induced acute kidney injury via inhibition of tubular ferroptosis. Biochem Biophys Res Commun 2023; 679:15-22. [PMID: 37659274 DOI: 10.1016/j.bbrc.2023.08.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 08/14/2023] [Accepted: 08/22/2023] [Indexed: 09/04/2023]
Abstract
Contrast-induced acute kidney injury (CI-AKI) has become the third leading cause of AKI acquired in hospital, lacking of effective interventions. In the study, we identified the renal beneficial role of 2, 2-dimethylthiazolidine hydrochloride (DMTD), a safer compound which is readily hydrolyzed to cysteamine, in the rodent model of CI-AKI. Our data showed that administration of DMTD attenuated the impaired renal function and tubular injury induced by the contrast agent. Levels of MDA, 4-hydroxynonenal, ferrous iron and morphological signs showed that contrast agent induced ferroptosis, which could be inhibited in the DMTD group. In vitro, DMTD suppressed ferroptosis induced by ioversol in the cultured tubular cells. Treatment of DMTD upregulated glutathione (GSH) and glutathione peroxidase 4 (GPX4). Moreover, we found that DMTD promoted the ubiquitin-mediated proteasomal degradation of Keap1, and thus increased the activity of nuclear factor erythroid 2-related factor 2 (Nrf2). Mechanistically, increase of the ubiquitylation degradation of Keap1 mediates the upregulated effect of DMTD on Nrf2. Consequently, activated Nrf2/Slc7a11 results in the increase of GSH and GPX4, and therefore leads to the inhibition of ferroptosis. Herein, we imply DMTD as a potential therapeutic agent for the treatment of CI-AKI.
Collapse
Affiliation(s)
- Bo Dai
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Qiuyue Su
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Xuan Liu
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Xue Mi
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Lin Dou
- Departments of Intensive Care Unit, Tianjin First Central Hospital, Tianjin, 300072, China
| | - Donghui Zhou
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Yu Su
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Tianyu Shen
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Yuying Zhang
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Wenqing Xu
- Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300072, China
| | - Xiaoyue Tan
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China
| | - Dekun Wang
- Department of Pathology, Medical School of Nankai University, Tianjin, 300072, China.
| |
Collapse
|